Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cholic acid Clear all
Terminated Phase 2 Interventional Results available

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

NCT00550862
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
INT-747, Ursodeoxycholic Acid (URSO), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Cholic Acid for Hepatic Steatosis in Lipodystrophy

NCT00457639
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
Cholic Acid
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 6, 2026, 9:10 AM EDT
Not listed Phase 2 Interventional

Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease

NCT00004315
View directory record Official record
Conditions
Cystic Fibrosis, Gastrointestinal Diseases, Cholestasis
Interventions
ursodiol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
4 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 9:10 AM EDT
Enrolling by invitation Phase 1 Interventional

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

NCT06300502
View directory record Official record
Conditions
Neurofibromas, Cutaneous, Neurofibromatosis 1
Interventions
Kybella
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01546142
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Not applicable Interventional

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

NCT01505569
View directory record Official record
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01426373
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
18
States / cities
Beverly Hills, California • La Jolla, California • San Juan Capistrano, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Smith-Lemli-Opitz Syndrome and Cholic Acid

NCT03720990
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Cholic Acid
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
2 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

NCT02684591
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, HIV
Interventions
Aramchol, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 6, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional Results available

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

NCT03602976
View directory record Official record
Conditions
Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
Interventions
Ursodeoxycholic Acid
Drug
Lead sponsor
Ethan Weinberg
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 6, 2026, 9:10 AM EDT
Completed No phase listed Observational

Cholate Clearance in Fontans

NCT03726229
View directory record Official record
Conditions
Fontan Procedure
Interventions
Cholate assay
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis

NCT01589523
View directory record Official record
Conditions
Bile Acid Synthesis Defect, Inborn Error of Bile Acid Metabolism, Inborn Error of Bile Acid Conjugation
Interventions
Glycocholic Acid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Week to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 6, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

NCT00062023
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

NCT06120036
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Kybella, Asclera
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

NCT02123134
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
65 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

NCT04640571
View directory record Official record
Conditions
Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions
pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

C. Difficile and Ursodiol

NCT02748616
View directory record Official record
Conditions
Diarrhea
Interventions
Ursodiol
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

NCT00422188
View directory record Official record
Conditions
Lipoma
Interventions
Deoxycholic Acid Injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 6, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional Results available

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

NCT02244944
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
EZ-Urso combination therapy
Drug
Lead sponsor
Gregory Graf, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

NCT01115582
View directory record Official record
Conditions
Inborn Errors of Bile Acid Synthesis
Interventions
Cholic acid
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01542034
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infant Fecal Insult Study

NCT02979210
View directory record Official record
Conditions
Dermatitis
Interventions
Artificial Fecal Insult, Phosphate Buffered Saline
Other
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 6, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional Results available

The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology

NCT03294941
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HepQuant SHUNT Liver Diagnostic Kit
Combination Product
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Dallas, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 6, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

NCT02967250
View directory record Official record
Conditions
Parkinson Disease
Interventions
ursodeoxycholic acid
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 6, 2026, 9:10 AM EDT